Vertex/CRISPR Nab First-Ever Gene Editing FDA Nod, Overshadow Bluebird’s Same-Day Win

The two first-ever therapies to offer sickle cell disease patients the possibility of lifetime relief from painful vaso-occlusive events or crises are hitting the market, but face tough commercial challenges.